Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
TNYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.36 - $4.06
Previous CloseN/A
Volume1.07M
Average Volume (3M)2.49M
Market Cap
$94.10M
Enterprise ValueN/A
Total Cash (Recent Filing)$61.45M
Total Debt (Recent Filing)$13.61M
Price to Earnings (P/E)―
Beta3.15
Next Earnings
Aug 06, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding162,666,930
10 Day Avg. Volume3,094,431
30 Day Avg. Volume2,494,465
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-1.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.33Price Target Upside1650.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Tenaya Therapeutics News
PremiumCompany Announcements
Tenaya Therapeutics Appoints New Directors at Annual Meeting
PremiumCompany Announcements
Tenaya Therapeutics Reports Q1 2025 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe company's gene therapy for MYBPC3-associated hypertrophic cardiomyopathy remains on track to complete enrollment in Cohort 2, setting up initial data from the cohort as well as additional data from Cohort 1.
Financial PerformanceTenaya has extended its cash runway into H2 2026 via a $48.8M equity raise, carrying the company through several key inflection points.
Regulatory EnvironmentThe agency’s commitment to rare disease with high unmet need is emphasized, which could benefit Tenaya's programs.
Bears Say
Financial ChallengesTenaya Therapeutics reported a net loss of $26.9 million in the first quarter of 2025.
Market SentimentTenaya’s shares were caught in a widespread biotech sell-off following Vinay Prasad’s appointment to head of the Center for Biologics Evaluation and Research.
PartnershipsRemove PoS-adjusted milestone payments for TN-301 in HFpEF as partnership no longer seems probable in the current environment.
Ownership Overview
72.98% Insiders
6.00% Mutual Funds
0.03% Other Institutional Investors
17.64% Public Companies and Individual Investors
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.36 and its highest was $4.06 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $94.10M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Aug 06, 2025 which is in 45 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on May 07, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$0.05.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 162,666,930 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (1650.85% Upside)
$10.33 (1650.85% Upside)
Hedge Fund Trend
Increased
By 5.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.59%
12-Months-Change
Fundamentals
Return on Equity
-76.21%
Trailing 12-Months
Asset Growth
-22.15%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
TNYA Stock 12 Month Forecast
Average Price Target
$10.33
▲(1650.85%Upside)
Technical Analysis
Veru
―
Black Diamond Therapeutics
―
Pliant Therapeutics
―
Elicio Therapeutics
―
Telomir Pharmaceuticals, Inc.
―